Anavex Life Sciences
AVXL
139 hedge funds and large institutions have $308M invested in Anavex Life Sciences in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 32 closing their positions.
120% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $9.48M
83% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 30
3.79% more ownership
Funds ownership: 29.08% → 32.87% (+3.8%)
7% less funds holding
Funds holding: 149 → 139 (-10)
20% less capital invested
Capital invested by funds: $383M → $308M (-$75.1M)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21.4M |
| 2 |
Morgan Stanley
New York
|
+$4.78M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.6M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
+$2.61M |
| 5 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.98M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.24M |
| 3 |
Citigroup
New York
|
-$1.74M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$1.04M |
| 5 |
Barclays
London,
United Kingdom
|
-$891K |
AVXL Hedge Fund Activity: Q1 2022 in Review
139 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q1 2022, worth a combined $308M — down 20% from $383M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of AVXL and 23 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 55 added.
The largest buyer was State Street, adding an estimated $21.4M. The largest seller was Invesco, cutting an estimated $4.98M.
- 139 institutional investors held Anavex Life Sciences (AVXL) as of Q1 2022, down from 149 in Q4 2021.
- Funds reported $308M of Anavex Life Sciences stock for Q1 2022, down 20% quarter-over-quarter.
- 23 funds opened new Anavex Life Sciences positions in Q1 2022 and 32 closed out, a net change of -9 holders.
- The largest Anavex Life Sciences buyer in Q1 2022 was State Street, an estimated $21.4M added.
- The largest Anavex Life Sciences seller in Q1 2022 was Invesco, an estimated $4.98M sold.
Based on aggregated 13F filings for Q1 2022.